![](https://www.gsk.com/assets/img/GSK_Logo_Full_Colour_RGB.png?mode=pad&width=350&height=157)
New data at ASCO showcases the transformational potential of GSK's oncology portfolio
DREAMM-8 results for Blenrep (belantamab mafodotin) in multiple myeloma featured in a late-breaking presentation and ASCO’s Press Programme Updated results from a supported collaborative study for Jemperli (dostarlimab) in locally advanced mismatch repair …